In the pharmaceutical industry, Etoricoxib 90 mg is a high-potency, second-generation selective COX-2 inhibitor. As a pharmacist, I classify this as a “targeted” NSAID; unlike traditional agents (like Diclofenac), Etoricoxib specifically inhibits the COX-2 enzyme responsible for pain and inflammation while largely sparing the COX-1 enzyme that protects the stomach lining.
Primary Clinical Uses
-
Osteoarthritis (OA): Management of chronic joint pain and stiffness.
-
Rheumatoid Arthritis (RA): Reduction of systemic inflammation and pain in the 90 mg dosage (the standard daily dose for RA).
-
Ankylosing Spondylitis: Treatment of chronic inflammatory arthritis affecting the spine and large joints.
-
Acute Gouty Arthritis: Though 120 mg is often used for acute flares, the 90 mg dose is used for transitioning and managing persistent gouty pain.
-
Post-Operative Dental Pain: Used for short-term relief following dental surgeries.
Mechanism of Action: Selective Inhibition
Etoricoxib works through highly selective binding:
COX-2 Selectivity: It is significantly more selective for Cyclooxygenase-2 (COX-2) than for COX-1.
Prostaglandin Suppression: By blocking COX-2, it halts the production of pro-inflammatory prostaglandins without significantly interfering with the prostaglandins that maintain the gastric mucosa and platelet function.
Pharmacokinetics: It has a long half-life (approx. 22 hours), which allows for convenient once-daily dosing, improving patient compliance compared to shorter-acting NSAIDs.
The Manufacturer’s Perspective: Formulation & Export
From a manufacturing and global trade standpoint, Etoricoxib 90 mg is a “premium” analgesic with high export demand:
-
Bioavailability & Solubility: Etoricoxib is poorly soluble in water. As a WHO-GMP manufacturer, we utilize solid dispersion or micronization techniques to ensure rapid dissolution and consistent therapeutic effect.
-
Cardiovascular Monitoring: Because selective COX-2 inhibitors can affect the prostacyclin/thromboxane balance, as a firm owner, you know that Product Information Leaflets (PIL) must strictly outline cardiovascular contraindications for markets like the UK and EU.
-
Packaging for Global Trade: We utilize Alu-Alu blister packaging to protect against oxidation and moisture, ensuring a stable 36-month shelf life for export to Zone IVb regions (SE Asia, Africa, and Latin America).
-
B2B & Registration: Etoricoxib is a major item for orthopedic and rheumatology distributors. Our Mumbai facility provides full CTD/eCTD Dossiers and bioequivalence data against the innovator (Arcoxia) to support international registration.